Head-to-head evidence
Bexagliflozin vs THR-1442
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: SGLT2 · full Type 2 Diabetes pipeline
Bexagliflozin · Brenzavvy
Marketed by Theracos
NCT02558296 · Phase 3 · completed
This was a large randomized, quadruple-blind, placebo-controlled trial with 1,700 participants, and its primary HbA1c comparison was statistically significant in favor of bexagliflozin. The grade is moderate because HbA1c is a surrogate measure rather than a hard clinical outcome.
Next expected readout: March 2029 · NCT07547878 (registry estimate)
THR-1442
Developed by Newsoara Biopharma
NCT05369078 · Phase 1 · status unknown
This was a small, non-randomized, unblinded study in healthy volunteers with no placebo or comparator arm, designed only to characterize safety and drug levels. Results have not yet been posted.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bexagliflozin's landscape · THR-1442's landscape